Summary
Compiles FDA accelerated approval precedents, surrogate endpoint acceptance history, and confirmatory trial requirements to support accelerated approval strategies.
Detailed Description
The Accelerated Approval Evidence Pack supports sponsors seeking FDA accelerated approval for serious oncology indications. It aggregates the FDA accelerated approval database, surrogate endpoint qualification history, and post-marketing commitment data to help sponsors build a compelling regulatory case.
The pack analyzes every oncology accelerated approval granted to date, identifying patterns in surrogate endpoint selection, effect size thresholds, and the characteristics of successful versus withdrawn approvals. It maps confirmatory trial requirements and timelines from recent accelerated approvals.
Output includes a surrogate endpoint justification document, a comparative analysis of accelerated approval precedents in your indication, and a confirmatory trial planning framework that addresses FDA's increasing scrutiny of post-marketing commitments.
Evidence Sources
| Source | Type | Description | Refresh |
|---|---|---|---|
| FDA Accelerated Approval Database | REGULATORY | Complete database of FDA accelerated approvals in oncology with surrogate endpoints and outcomes | Monthly |
| Surrogate Endpoint Catalog | CURATED | Curated catalog of surrogate endpoints with qualification status and historical acceptance data | Monthly |
| Post-Marketing Commitment Tracker | REGULATORY | FDA post-marketing requirement and commitment database for accelerated approvals | Monthly |
Regulatory Mapping
Accelerated Approval of New Drugs for Serious Conditions
Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses
Accelerated Approval of Biological Products for Serious or Life-Threatening Illnesses
Agent Transparency
When you run this pack, your request is processed by a pipeline of specialized AI agents. Each agent operates with a defined confidence threshold and is auditable end-to-end.
Evidence Retriever
brew-retriever-v3
Queries curated sources for relevant evidence objects. Searches across regulatory databases, clinical registries, and scientific literature to surface the most pertinent references for the pack domain.
Domain Analyzer
brew-domain-analyst-v2
Applies domain-specific reasoning and regulatory mapping. Interprets evidence in the context of FDA, ICH, and EMA frameworks and tags each finding with the relevant guidance references.
Evidence Synthesizer
brew-synthesizer-v2
Synthesizes findings into structured output. Combines retrieved evidence and domain analysis into a cohesive narrative with quantitative summaries, comparative tables, and actionable recommendations.
Output Validator
brew-validator-v1
Validates citations, checks confidence thresholds, and ensures all referenced sources are accessible and correctly attributed. Flags any claims that fall below the confidence floor.
Sample Outputs
Surrogate Endpoint Justification
PDFEvidence-based rationale for the proposed surrogate endpoint with historical qualification data
Accelerated Approval Precedent Analysis
PDFDetailed comparison of precedent accelerated approvals in the target indication with outcomes
Confirmatory Trial Framework
XLSXPlanning framework for confirmatory trial including timeline, endpoint, and enrollment projections
Deliverables included
- Surrogate endpoint justification document
- Accelerated approval precedent analysis (20+ precedents)
- Confirmatory trial design framework
- Risk assessment for accelerated approval withdrawal
- Post-marketing commitment planning template
Related Disease & Biomarker Mappings
| Therapeutic Area | Disease Family | Key Biomarkers | Relevance |
|---|---|---|---|
| Solid Tumors | Non-Small Cell Lung Cancer | EGFRALKPD-L1KRAS G12C | Primary |
| Solid Tumors | Breast Cancer | HER2ER/PRBRCA1/2PIK3CA | Primary |
| Hematologic Malignancies | Acute Myeloid Leukemia | FLT3-ITDIDH1/2NPM1 | Secondary |
| Solid Tumors | Colorectal Cancer | KRAS/NRASBRAF V600EMSI-H/dMMR | Secondary |
Related Packs in Oncology
Oncology Trial Design Pack
Design smarter trials with real-world precedent data
Dose Optimization Pack (Project Optimus)
Navigate the new dose optimization paradigm with confidence
Biomarker-Driven Trial Design Pack
Turn molecular insights into registration-ready trial designs
Immuno-Oncology Combination Pack
Build the regulatory case for your IO combination
Version History
Current release — expanded evidence sources, improved citation accuracy, and added new regulatory cross-references.
Beta release — validated with domain SMEs. Added sample output previews and refined confidence scoring.
Initial draft — core evidence retrieval pipeline and output schema established.
Need a Custom Evidence Pack?
Our enterprise team can build bespoke evidence packs tailored to your therapeutic area, regulatory strategy, or internal decision framework. Custom packs include dedicated evidence source curation, domain-specific agent tuning, and priority SLA support.
Enterprise packs are available for organizations on the BrewBio Pro or Enterprise plan.